Phathom Pharmaceuticals Stock (NASDAQ:PHAT)
Previous Close
$12.16
52W Range
$2.21 - $18.31
50D Avg
$11.59
200D Avg
$12.50
Market Cap
$921.94M
Avg Vol (3M)
$1.06M
Beta
0.61
Div Yield
-
PHAT Company Profile
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.